6Veronika Jekerle,Werner Klinkhammer,Raymond M. Reilly,Micheline Piquette-Miller,Michael Wiese.Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties[J]. Cancer Chemotherapy and Pharmacology . 2007 (1)
7T.W. Loo,D.M. Clarke.Recent Progress in Understanding the Mechanism of P-Glycoprotein-mediated Drug Efflux[J]. Journal of Membrane Biology . 2005 (3)
8Molnar J,Engi H,Hohmann J,etal.Reversal of multidrug resitanceby natural substances from plants. Current Topics in Medicinal Chemistry . 2010
9Wang Z,Ravula R,Cao M,et al.Transporter-mediated multidrug re-sistance and its modulation by Chi-nese medicines and other herbalproducts. Curr Drug DiscovTechnol . 2010
10O Connor R.The pharmacology ofcancer resistance. Anticancer Research . 2007
2Gottesman M M, Fojo T, Bates S E. Multidrug resistance in cancer: role of ATP-dependent transporters[J]. Nat Rev Cancer, 2002, 2: 48-58.
3Gottesman M M, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter[J]. Ann Rev Biochem, 1993, 62: 385-427.
4Witherspoon S M, Emerson D L, Kerr B M, et al. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918[J]. Clin Cancer Res,1996, 2:7-12.
5Ferry D R, Traunecker H, Kerr D J. Clinical trials of P-glycoprotein reversal in solid tumours[J]. Eur J Cancer, 1996, 32A:1070-1081.
6John P F. In vitro drug response and biomarker profiles for ovarian cancer specimens obtained at initial debulking or after neoadjuvant chemotherapy (EORTC 55971)[C]. 2002 ASCO Annual Meeting, Philadelphia, PA, USA, American Society of Hematology, December 06-10, 2002.
7Ikumi T, Ahmad R. Competitive interaction of cyclosporins with the vinca Alkaloid-binding site of P-glycoprotein in multildrug-resistant cells[J]. J Biological Chemistry, 1990, 265(27):16509-16513.
8Krishna R, Mayer L D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs[J]. Eur J Pharm Sci, 2000, 11: 265-283.
9te Boekhorst P A, van Kapel J, Schoester M, et al. Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype[J]. Cancer Chemother Pharmacol, 1992, 30:238-242.
10Giaccone G, Linn S C, Welink J, et al. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors[J]. Clin Cancer Res. 1997, 3:2005-2015.
10Nelson DA, Tan TT, Rabson AB, et al. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis [ J ]. Genes Dev, 2004, 18 (17):2095-2107.
